@article{3103348,
    title = "Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries",
    author = "Balak, D.M.W. and Carrascosa, J.-M. and Gregoriou, S. and Calzavara-Pinton, P. and Bewley, A. and Antunes, J. and Nyeland, M.E. and Viola, M.G. and Sawyer, L.M. and Becla, L.",
    journal = "Journal of Dermatological Treatment",
    year = "2021",
    volume = "32",
    number = "7",
    pages = "701-708",
    publisher = "Taylor and Francis Ltd.",
    issn = "0954-6634, 1471-1753",
    doi = "10.1080/09546634.2019.1707754",
    keywords = "apremilast;  betamethasone dipropionate plus calcipotriol;  dimethyl fumarate;  etretin;  methotrexate;  betamethasone;  betamethasone-17,21-dipropionate;  calcipotriol;  calcitriol;  dermatological agent, adult;  Article;  Belgium;  clinical effectiveness;  comparative effectiveness;  controlled study;  cost effectiveness analysis;  drug cost;  drug dose escalation;  drug dose increase;  drug dose titration;  European Medicines Agency;  foam;  follow up;  Greece;  human;  Italy;  major clinical study;  Netherlands;  observational study;  Portugal;  Psoriasis Area and Severity Index 75;  psoriasis vulgaris;  Spain;  systemic therapy;  topical treatment;  treatment duration;  treatment response;  United Kingdom;  drug combination;  psoriasis;  treatment outcome, Betamethasone;  Calcitriol;  Dermatologic Agents;  Drug Combinations;  Humans;  Psoriasis;  Treatment Outcome",
    abstract = "Purpose: To compare the short-term cost and effectiveness of calcipotriol/betamethasone dipropionate (Cal/BD) cutaneous foam against nonbiologic systemics in psoriasis patients for whom oral systemic or topical therapy is considered appropriate in seven European countries. Methods: Matching-adjusted indirect comparisons of four-week PASI-75 responses of Cal/BD foam were performed versus 12-week responses of methotrexate, acitretin, fumaric acid esters (FAE) and 16-week responses of apremilast. Analyses took a payer perspective and included drug, physician visit and monitoring costs. Results: In all countries, Cal/BD foam generated the lowest cost per responder (CPR). Against methotrexate, apremilast and acitretin, Cal/BD foam generated response for less than €190 in Italy, €195 in Portugal, €216 in Greece, £218 in the United Kingdom, €250 in Belgium, €319 in Spain, and €359 in the Netherlands. Relative to treatment with FAE, Cal/BD foam resulted in response for less than €298, €430, €382 and £262 in Belgium, the Netherlands, Spain and the United Kingdom, respectively. For Cal/BD foam, apremilast and FAE, total costs were driven by drug costs; for methotrexate and acitretin, by monitoring. Conclusions: Driven by its lower costs and high response rates, Cal/BD foam is likely to be a cost-effective option over the short-term in the investigated psoriasis population. © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC."
}